# OnCo record akamis-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/akamis-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "akamis-bio" ;
  schema:name "Akamis Bio"@en ;
  schema:alternateName "Akamis Bio, Inc."@en ;
  schema:description "Akamis Bio develops cancer-killing viruses, given into a vein, that are built to carry extra immune-stimulating genes into tumours. It is focused on bowel cancer, first in locally advanced rectal cancer."@en ;
  schema:url <https://onco.cc/companies/akamis-bio/>, <https://www.akamisbio.com/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.akamisbio.com/>, <https://www.akamisbio.com/science-pipeline/pipeline/>, <https://www.akamisbio.com/patient-community/clinical-trials/>, <https://www.akamisbio.com/news/akamis-bio-announces-60-million-in-funding-linked-to-series-a-prime-financing-and-new-strategic-partnership/>, <https://www.akamisbio.com/news/akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026/>, <https://clinicaltrials.gov/study/NCT06459869>, <https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:targets <https://onco.cc/targets/cd40/>, <https://onco.cc/targets/cd80/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/ng-350a/>, <https://onco.cc/drugs/ng-348/> .